Peritumoral injections of interleukin 2 induce tumour regression in metastatic malignant melanoma.

No abstract is available for this paper.

• Publication year

  1994

• Venue

  British Journal of Dermatology

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  PMID 8186129
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• T cells migrate to tumour sites after extracorporeal interleukin 2 stimulation and reinfusion in a patient with metastatic melanoma

  1993cited by this paper
• Successful therapy of metastatic eccrine poroma using perilesional interferon alfa and interleukin 2.

  1992cited by this paper
• A case of malignant haemangioendothelioma showing response to interleukin 2 therapy

  1992cited by this paper
• Continuous interleukin‐2 and tumor‐infiltrating lymphocytes as treatment of advanced melanoma. A national biotherapy study group trial

  1991cited by this paper
• The skin: an immunoreactive target organ during interleukin-2 administration?

  1991cited by this paper
• Lymphokines and cytokines as cancer treatment.Immunotherapy realized

  1990cited by this paper
• A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone.

  1987cited by this paper

• Topical and Intralesional Treatments for Skin Metastases and Locoregionally Advanced Melanoma

  2024cites this paper
• Advances and Challenges in Interventional Immuno-Oncology Locoregional Therapies.

  2024cites this paper
• Alternative Strategies for Delivering Immunotherapeutics Targeting the PD-1/PD-L1 Immune Checkpoint in Cancer

  2024cites this paper
• Advances in Intralesional Therapy for Locoregionally Advanced and Metastatic Melanoma: Five Years of Progress

  2023cites this paper
• Intratumoural administration and tumour tissue targeting of cancer immunotherapies

  2021cites this paper
• Managing in-transit melanoma metastases in the new era of effective systemic therapies for melanoma

  2019cites this paper
• Immunomodulation of the Tumor Microenvironment: Turn Foe Into Friend

  2018cites this paper
• Intralesional treatment of metastatic melanoma: a review of therapeutic options

  2017cites this paper
• Intralesional administration of L19-IL2/L19-TNF in stage III or stage IVM1a melanoma patients: results of a phase II study

  2015cites this paper
• In situ vaccination: Cancer immunotherapy both personalized and off‐the‐shelf

  2015cites this paper
• Targeting the tumor microenvironment to enhance antitumor immune responses

  2014cites this paper
• Intralesional Treatment of Stage III Metastatic Melanoma Patients with L19–IL2 Results in Sustained Clinical and Systemic Immunologic Responses

  2014cites this paper
• Armed antibodies for cancer treatment: a promising tool in a changing era

  2014cites this paper
• Microinvasive Melanoma

  2013cites this paper
• A Dose-Escalation and Signal-Generating Study of the Immunocytokine L19-IL2 in Combination with Dacarbazine for the Therapy of Patients with Metastatic Melanoma

  2011influential citation
• Survival after intratumoral interleukin-2 treatment of 72 melanoma patients and response upon the first chemotherapy during follow-up

  2011cites this paper
• High response rate after intratumoral treatment with interleukin‐2

  2010cites this paper
• Clinical application of dendritic cells and interleukin-2 and tools to study activated T cells in horses--first results and implications for quality control.

  2009cites this paper
• Chemoimmunotherapy of murine mammary adenocarcinomas.

  2004cites this paper
• Phase II trial of intralesional therapy with interleukin-2 in soft-tissue melanoma metastases

  2003cites this paper
• Tumor regression of human and murine melanoma after intratumoral injection of IL‐12‐encoding plasmid DNA in mice

  2002cites this paper
• Duration of gluten exposure in adult coeliac disease does not correlate with the risk for autoimmune disorders

  2001cites this paper
• Subcutaneous interleukin-2 and interferon-alpha therapy associated with cisplatin monochemotherapy in the treatment of metastatic melanoma.

  1998cites this paper
• Site-specific delivery of cytokines in cancer.

  1996cites this paper